中国实用外科杂志

中国实用外科杂志

• 论蓍 • 上一篇    下一篇

氟维司群联合曲妥珠单抗对人乳腺癌BT-474细胞株协同作用研究

陈    青，吴克瑾，丁龙龙，陆云姝，柏    方   

  1. 上海交通大学医学院附属新华医院普外科，上海 200092
  • 出版日期:2015-07-01 发布日期:2015-06-30

  • Online:2015-07-01 Published:2015-06-30

摘要：

目的    探讨氟维司群联合曲妥珠单抗对人乳腺癌BT-474细胞株的作用。方法    WST-1、Annexin/PI法分别测氟维司群、曲妥珠单抗单独与联合对BT-474细胞株增殖抑制率及凋亡率，Western blot法测药物对p-Akt、p-MAPK蛋白表达影响。结果    各组对BT-474细胞增殖抑制作用有浓度依赖性，CIED50=0.466，联合组较单药组凋亡率增高（P<0.05），氟维司群组p-Akt、p-MAPK蛋白表达增高，联合组较氟维司群组明显降低。结论    氟维司群联合曲妥珠单抗对BT-474细胞作用协同，可能与增强抑制细胞增殖、促进细胞凋亡及抑制氟维司群增高p-Akt、p-MAPK蛋白表达有关。

关键词: 乳腺肿瘤, BT-474, 氟维司群, 曲妥珠单抗

Abstract:

Research on the effectiveness of fulvestrant combined with trastuzumab on the human breast cancer cell line BT-474        CHEN Qing, WU Ke-jin, DING Long-long, et al. Department of General Surgery, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
Corresponding author: WU Ke-jin, E-mail: kejinwu@163.com
Abstract    Objective    To investigate the effectiveness of fulvestrant combined with trastuzumab on the human breast cancer cell line BT-474.Methods    Inhibition of BT-474 cell proliferation at different concentrations of fulvestrant, trastuzumab and the two drugs combined was assessed using the WST-1 assay.Flow cytometry(FCM) was used to detect the cell apoptosis rates by Annexin-V/PI assay. Moreover, the effect fulvestrant and trastuzumab respectively and combinedly have on the proteins p-Akt and p-MAPK was detected by Western blot assay. Results    The cell proliferation was increasingly inhibited by fulvestrant, trastuzumab or them combined when each group’s drug concentration added, with a CIED50 of 0.466.When fulvestrant and trastuzumab combined, the cell apoptosis rates were distinctly increased(P<0.05).Furthermore, the level of proteins p-Akt and p-MAPK expressed in the cell BT-474 was raised by fulvestrant, but definitively reduced when fulvestrant combined with trastuzumab. Conclusion    Fulvestrant synergizes trastuzumab if they combine when acing on the cell line BT-474, maybe because fulvestrant combined with trastuzumab increases the cell proliferation inhibition, promotes the cell apoptosis and restrains fulvestrant from enhancing the proteins p-Akt and p-MAPK expression.

Key words: breast neoplasm, BT-474, fulvestrant, trastuzumab